Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"The Company also announced that, effective July 1, 2021, the Depository Trust Company (“DTC”) deemed the Company’s common shares eligible for electronic clearing and settlement through DTC. DTC is a subsidiary of the Depository Trust & Clearing Corporation, a company that manages the electronic clearing and settlement of publicly traded securities"
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001438943/000149315221021902/form8-k.htm
There is a legitimate management team in place, and the riff raff was kicked to the curb in 2019.
Finally. Perseverance will pay off. NASDAQ listed may very well come some day. Is it $4 and above for 30 days before they can file? I know there is a ways to go before this from company name change to more pipeline news, etc.
Congrats fellow longs
The Best Week in 3 Years!
VBIO...695...off my .16 range alert...Bearish 3 Gap Ups...Took some profit on this Bearish set up...Will ride the rest to see how VBIO reacts...Long term...I think it Breaks $2 range...imo...we shall see...:partying_face:
I watched one of their scientific presentations a few years ago. The cannabosides are real deal. I believe they have patents on dozens of them
why is this stock going up so much? what do they have thats so hot???
thx
go vbio go
VBIO...57s clearing here off the .16 range alert...:partying_face:
VBIO...50...Hod on the close...Break/Hold the Double Top here...we see the $1 range...imo...we shall see...
Chart... https://schrts.co/wvPzUBPK ...
[4:07 PM]
georgie18 Thursday, 05/13/21 08:46:43 AM
Re: None 0
Post #
2332
of 2371
VBIO...167... entering on the "CE" Removal...:party:
The millennials are investing in VBIO. Just who we want to invest. https://www.tritonfunds.com/
$VBIO Vitality Biopharma Enters Into $5 Million Equity Line Financing Relationship With Institutional Investor
Press Release | 08/20/2021
CLEVELAND, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic powers of cannabinoids, today announced that the Company had entered into a definitive agreement with an institutional investor for a $5,000,000 equity line financing.
Under the terms of the equity line financing, once the registration statement covering these shares is declared effective, the institutional investor is obligated to purchase the number of shares of the Company’s common stock set forth in each purchase notice delivered by the Company until December 31, 2022 (up to $250,000 per purchase notice) at a price equal to 85% of the share’s lowest daily volume weighted average price over the five-day period prior to the pricing date, up to an aggregate value of $5,000,000. For each share sold to the institutional investor, the Company also will issue a warrant for another share exercisable at 115% of the lowest daily volume weighted average price of the five-day period prior to the pricing date.
The Company anticipates using the proceeds from the offering to advance the Company’s leading prodrug candidate, VBX-100, through its pre-clinical studies and for general corporate purposes. VBX-100, a glycosylated cannabinoid developed using our proprietary enzymatic bioprocessing technologies, was recently granted Orphan Drug Designation by the FDA for the treatment of pediatric ulcerative colitis.
“Over the past two and a half years our management team has successfully executed our three-pronged corporate recovery plan to resume ordinary course trading of our common stock, strengthen our balance sheet, and invest in our drug development assets. Today we are excited to announce this $5 million equity line financing which we expect will provide the critical funding necessary to support our transition into the value creation phase of our strategic plan, with a particular focus on advancing our VBX-100 prodrug through preclinical studies,” said Michael Cavanaugh, Chief Executive Officer of Vitality. “This financing is structured in a manner to allow us to draw capital on an as-needed basis to minimize dilution and maximize return on invested capital. We are thankful for the commitment and creativity of our institutional investor financing partner.”
About Vitality Biopharma, Inc.
Headquartered in Los Angeles, California, Vitality Biopharma, Inc. (www.vitality.bio) is a company focused on the advancement of pharmaceuticals and innovative technologies that improve the lives of patients. Vitality seeks to achieve this objective through the development of novel glycosylated cannabinoid prodrugs that are engineered to deliver the therapeutic benefits of cannabinoids but without their unwanted side effects. Vitality has developed over 100 novel cannabinoid compounds, including glycosylated tetrahydrocannabinol (THC) and water soluble glycosylated cannabidiol (CBD) prodrugs.
Notice Regarding Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors that could cause actual outcomes and results to be materially different from those indicated in such statements. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, timing of clinical trials and product development, business strategy and new lines of business. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Vitality Biopharma, Inc.
Investor Relations
info@vitality.bio
+1 530.231.7800
www.vitality.bio
VITALITY BIOPHARMA ENTERS INTO $5 MILLION EQUITY LINE FINANCING RELATIONSHIP WITH INSTITUTIONAL INVESTOR
VBIO...32...https://www.otcmarkets.com/stock/VBIO/news/story?e&id=1977677 ...“Over the past two and a half years our management team has successfully executed our three-pronged corporate recovery plan to resume ordinary course trading of our common stock, strengthen our balance sheet, and invest in our drug development assets. Today we are excited to announce this $5 million equity line financing which we expect will provide the critical funding necessary to support our transition into the value creation phase of our strategic plan, with a particular focus on advancing our VBX-100 prodrug through preclinical studies,” said Michael Cavanaugh, Chief Executive Officer of Vitality. “This financing is structured in a manner to allow us to draw capital on an as-needed basis to minimize dilution and maximize return on invested capital. We are thankful for the commitment and creativity of our institutional investor financing partner.”...:party:
[9:04 AM]
georgie18 — 08/10/2021
VBIO...23...https://www.otcmarkets.com/stock/VBIO/news/FDA-Grants-Vitality-Biopharma-Orphan-Drug-Designation-for-VBX-100-Prodrug?id=315622 ... :party:
georgie18 Thursday, 05/13/21 08:46:43 AM
Re: None 0
Post #
2332
of 2357
VBIO...167... entering on the "CE" Removal...:party:
$331,138 in the bank, June 30th.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1438943/000149315221019705/form10-q.htm
$VBIO FDA Grants Vitality Biopharma Orphan Drug Designation for VBX-100 Prodrug
Press Release | 08/10/2021
CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic powers of cannabinoids, today announced that the U.S. Food and Drug Administration (“FDA”) granted Orphan Drug Designation to its glycosylated cannabinoid prodrug VBX-100 for the treatment of pediatric ulcerative colitis.
“The FDA’s granting of Orphan Drug Designation for VBX-100, our leading glycosylated cannabinoid for the treatment of inflammatory conditions of the gastrointestinal tract, is a significant milestone for our drug development program,” said Brandon Zipp, Ph.D., Chief Science Officer of Vitality. “We look forward to accelerating our research efforts to develop safe and effective novel treatments for chronic disorders such as IBS and inflammatory diseases such as IBD, particularly ulcerative colitis in children.”
“We believe that our broad portfolio of over 100 novel glycosylated-cannabinoid compounds, developed using our proprietary enzymatic bioprocessing technologies, possesses significant medicinal potential,” added Michael Cavanaugh, Chief Executive Officer of Vitality. “The FDA’s granting of Orphan Drug Designation to one of our initial novel compounds reaffirms our commitment to the pursuit of additional therapeutic applications for our scores of unique glycosylated cannabinoid molecules.”
The FDA’s Office of Orphan Products Development grants orphan status to drugs intended for the safe and effective treatment, diagnosis or prevention of rare diseases or conditions affecting fewer than 200,000 people in the United States. Orphan Drug Designation provides drug developers with various benefits designed to support the development of novel drugs, including market exclusivity for seven years upon FDA approval, tax credits for qualified clinical trials, and exemption from FDA application fees.
About Vitality Biopharma, Inc. (OTC: VBIO)
Headquartered in Los Angeles, California, Vitality Biopharma, Inc. (www.vitality.bio) is a company focused on the advancement of pharmaceuticals and innovative technologies that improve the lives of patients. Vitality seeks to achieve this objective through the development of novel glycosylated cannabinoid prodrugs that are engineered to deliver the therapeutic benefits of cannabinoids but without their unwanted side effects. Vitality has developed over 100 novel cannabinoid compounds, including glycosylated tetrahydrocannabinol (THC) and water soluble glycosylated cannabidiol (CBD) prodrugs.
Notice Regarding Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors that could cause actual outcomes and results to be materially different from those indicated in such statements. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, timing of clinical trials and product development, business strategy and new lines of business. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Vitality Biopharma, Inc.
Investor Relations
info@vitality.bio
+1 530.231.7800
Well, first you still can't buy on many accounts such as Meryl Lynch, never mind an app like Robinhood and it has to be cash even in TD. Things will change soon though. Tomorrow is the vote and lots of things start to finally go forward.
More selling than buying doesn't do much for share price.
Surprised there isn't more volume today
VBIO...33s clearing here on the Upper Bollie Break...plus 60%...:partying_face:
VBIO...23...https://www.otcmarkets.com/stock/VBIO/news/FDA-Grants-Vitality-Biopharma-Orphan-Drug-Designation-for-VBX-100-Prodrug?id=315622
georgie18 Thursday, 05/13/21 08:46:43 AM
Re: None 0
Post #
2332
of 2357
VBIO...167... entering on the "CE" Removal...
VBIO will have a shareholder meeting on August 12th in Cleveland.
Wow. That’s probably the most complete shareholder update I’ve ever seen from a CEO.
Good shit coming soon
Looks like there may be some positive developments ahead. https://vitality.bio/ceo-letter-to-shareholders/
It is pretty evident that Cavanaugh is a straight shooter. Whether or not they can resurrect the company with a name change, remains to be seen.
For them not saying anything for 2 years this investor letter says a lot and makes sense.
I like the Final Thoughts
The past two years have presented a number of challenges – and opportunities – for our officers, directors, employees and shareholders. Our entire team has worked tirelessly to navigate through these challenges, capitalize on opportunities, and execute our corporate recovery plan in order to reposition Vitality for future success. On behalf of our officers and directors, I would like to express our gratitude to each Vitality shareholder for your patience and support of our efforts. Our team still has a lot more work to do but we are highly motivated and confident that better days are ahead for Vitality and its shareholders.
Hopefully they have some good news up their sleeve after the name change.
They seem very confident.
A new name is coming. Malachite Innovations, Inc.
https://www.sec.gov/Archives/edgar/data/0001438943/000149315221014888/formdef14a.htm
108,000 shares sold and only 7,000 bought today. Not looking good.
They retained DelMorgan on September 25th of last year.
It could rip up so easily. Just need the right partners and PR. It's clear current management needs to let their baby go.
Waiting for positive news from VBIO. Otherwise, normal trading won't amount to a hill of beans.
its idiots who prolly bought higher and are off to chase something else- nutz w tiny float and good looking MMJ co- dollar potential easy w some patience
Since September 25th, 2020, there have been no company 8K's or news releases. And they are out of money. Hard to build value on that. No news on the DelMorgan M&A item.
VBIO .1658 RED on day CE is removed, a lot of dumping for sure not knowing if it's co or idiots or MM"S trying to get trades, but quite a pathetic display on VBIO's part imo
Now, VBIO needs to build value. A lot of selling going on today, pulling the price back down.
under market activity upper left , scroll down to corporate actions-
then under symbol changes scroll down to bottom CE
Is there a page where OTC Markets "announces" changes to CE status (i.e., a list of stocks getting a CE on that day and a list of those with the CE being removed that day), or do you just have to go to the page for each individual ticker and check if the CE is still there?
Not quite. "Held at DTC" means the total shares held by retail in "street name" at their respective brokers. It is possible that other shares are held in certificate form that would also add to the float, but in most cases the DTC number is a pretty good approximation of the (immediately) tradable float.
Not quite. "Held at DTC" means the total shares held by retail in "street name" at their respective brokers. It is possible that other shares are held in certificate form that would also add to the float, but in most cases the DTC number is a pretty good approximation of the (immediately) tradable float.
im not positive, but i take the held at DTC # as the tradeable float
Followers
|
58
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2432
|
Created
|
03/05/12
|
Type
|
Free
|
Moderators |
Vitality Biopharma (“Vitality”) (OTCQB: VBIO) is a cure development company, dedicated to unlocking the power of cannabinoid “prodrugs” as a means to treat serious neurological and inflammatory disorders. We are interested in drug approvals first and foremost, but our overarching mission is to improve the lives of patients afflicted with devastating neurological and inflammatory conditions, such as multiple sclerosis. We aim to go beyond providing symptomatic relief to patients afflicted with these disorders, such as treatment of muscle spasticity in multiple sclerosis, and to instead identify combination treatments that treat the underlying cause of disease and hold the potential to help patients recover lost function.
Prodrugs are medications or compounds that, after administration, are converted within the body into a pharmacologically active drug, which may already have a long history of clinical investigation and use. Because the reference drug already has independent verification of its safety and efficacy, the prodrug may be approved rapidly through demonstrating similar bioavailability or bioequivalence, and at the same time a prodrug can be far more marketable due to its ability to eliminate unwanted side effects or undesirable commercial aspects. A classic prodrug example is Aspirin, acetylsalicylic acid, which was first made by Felix Hoffmann at Bayer in 1897 and is a synthetic prodrug of salicylic acid. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.
One of the most hotly pursued cannabinoids for pharmaceutical purposes is cannabidiol, which is non-psychotropic, and has demonstrated therapeutic effects in clinical trials for serious neurological conditions including rare seizure disorders and for alleviating symptoms of multiple sclerosis. Our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as a better tasting formulation that enables improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, or a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief. Given that we have recently filed intellectual property applications including strong composition of matter claims for more than 30 cannabinoid prodrugs, including versions of THC, CBD, and CBDV, we have demonstrated the ability to create a proprietary prodrug of every significant cannabinoid pharmaceutical available today.
Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation.
Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease patients experience symptomatic relief, including more than 75% of patients who report improvement in visceral pain and abdominal cramping. Approximately 1.4 million Americans are affected by inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment.
In addition to providing targeted delivery, cannabosides could enable a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that enables patients using these medications to have long-lasting, overnight relief.A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. Prodrugs are often designed to improve bioavailability when a drug itself is poorly absorbed from the gastrointestinal tract, or to overcome other issues that make molecules unappealing candidates for future development efforts. A prodrug may for instance be used to selectively target a specific tissue or organ, such as the brain or gut, which enables the drug to have a more targeted effect. Prodrugs have been around for a while, with Aspirin, acetylsalicylic acid, first made by Felix Hoffmann at Bayer in 1897, a classic example of a synthetic prodrug of salicylic acid. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion.
Our compounds take advantage of a targeted-release mechanism where microbial enzymes present in the intestines will enable a very site-specific localized release of compounds including THC, CBD, and many of the other known cannabinoids. Because of this, we could provide targeted relief of inflammatory bowel diseases (IBD) such as Crohn’s disease or ulcerative colitis, simply by enabling larger doses of cannabinoids to be delivered.
click photo to view presentation
Through extensive research in the natural sweetener industry, we pioneered industrial-scale processes to modify stevia to make it taste better. This process is known as glycosylation, which involves adding additional glucose molecules to it, and it modifies both the taste and solubility of it. Over the last 10 years or so, it has become appreciated within the pharmaceutical industry that glycosylation could act to generate new natural product libraries with improved drug properties. This process for modifying natural products to make them more useful is often called glycorandomization, or glycodiversification.
Using the same technology, we’ve now been able to produce and characterize more than 20 novel cannabinoid glycosides, or “cannabosides”, which are novel cannabinoid prodrug pharmaceuticals. As an example, one of the most hotly pursued cannabinoids for pharmaceutical purposes is cannabidiol, which is non-psychotropic, and has potential therapeutic effects in a wide variety of serious neurological and inflammatory conditions. Our prodrugs could exert the same beneficial therapeutic effects, but with notable improvements, such as site-specific delivery that avoids or reduces psychoactivity, a better tasting formulation for improved patient compliance, better oral bioavailability that provides safer and more reliable dosing, and a delayed release mechanism that could enable long-lasting, overnight relief.
Vitality has filed intellectual property applications including strong composition of matter claims for prodrugs of THC, CBD, and CBDV, creating proprietary prodrugs of every significant cannabinoid pharmaceutical available today.
Vitality Biopharma, Inc.
1901 Avenue of the Stars
2nd Floor
Los Angeles, California
90067
Telephone: (530) 231-7800
Fax: (866) 293-0655
Email: info@vitality.bio
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |